A Seamless Phase II/III, Observer-blind, to Evaluate Immunogenicity and Safety of Chikungunya Virus Vaccine in Healthy Subjects 12-65Years of Age.

NCT07555392 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

1000

Enrollment

INDUSTRY

Sponsor class

Conditions

Active Immunisation for Chikungunya Virus Infection

Interventions

BIOLOGICAL: BBV87 Chikungunya vaccine
BIOLOGICAL: Placebo

Sponsor

Bharat Biotech International Limited